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Abstract 
Objective: Apolipoprotein E (ApoE) has been extensively studied in Alzheimer's disease (AD), 
but relatively little is known of apolipoprotein A-I (ApoA-I) in cerebrospinal fluid (CSF).  
Material and methods. In a mono-center study, consecutive patients with AD (n = 29), stable 
MCI (SMCI, n = 13), other dementias (n = 14), and healthy controls (n = 18) were included. 
We measured ApoA-I and ApoE concentrations in plasma and CSF as well as plasma lipid 
concentrations.  
Results. AD patients had higher plasma triglycerides and lower CSF ApoA-I concentration than 
controls (both P < 0.05). CSF ApoE concentration was reduced in other dementias (P < 0.01). 
In AD as well as other dementias, the ratios between CSF and plasma concentrations of both 
ApoA-I and ApoE were lower than those in the controls. Serum and CSF concentrations of 
ApoA-I and ApoE were not influenced by APOE ε4 allele distribution. In the total study 
population (n = 74), CSF ApoA-I correlated positively with mini mental state examination 
(MMSE) score (r = 0.26, P < 0.05) and negatively with CSF P-tau (r = -0.25, P < 0.05). CSF 
ApoE correlated positively with CSF concentrations of T-tau and P-tau in the total study 
population and in AD patients.  
Conclusion: CSF ApoA-I was lower in AD patients compared with controls and associated with 
measures of cognitive function and AD disease status. The mechanisms underlying the 
decreased CSF:plasma ratios of ApoA-I and ApoE observed in AD and other dementias need 
to be explored in further studies.    
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Introduction 
High-density lipoproteins (HDLs) eliminate excess cholesterol by transporting cholesterol from 
peripheral tissues to the liver [1]. Low-density lipoproteins (LDLs) carry the major part of 
plasma cholesterol and supply cholesterol to many cells [1]. Low levels of HDL and the 
associated apolipoprotein A-I (ApoA-I), and elevated LDL, are risk factors for atherosclerosis 
[1]. Although an impaired lipid pattern has been associated with increased dementia risk [2], it 
is controversial whether lipid-lowering statin treatment can affect the progression of 
Alzheimer’s disease (AD) [2]. In contrast to plasma, most CSF lipoproteins are HDL-like in 
both density and size (HOLTZMAN, D. M., BALES, K. R., WU, S., BHAT, P., 
PARSADANIAN, M., FAGAN, A. M., CHANG, L. K., SUN, Y. & PAUL, S. M. 1999. 
Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of 
Alzheimer's disease. J Clin Invest, 103, R15-R21; BORGHINI, I., BARJA, F., POMETTA, D. 
& JAMES, R. W. 1995. Characterization of subpopulations of lipoprotein particles isolated 
from human cerebrospinal fluid. Biochim Biophys Acta, 1255, 192-200). 
Apolipoprotein E (ApoE), produced by the liver and for example macrophages [3], is found in 
several types of lipoprotein particles [3]. In the central nervous system (CNS), ApoE is mainly 
produced by astrocytes and microglia [3]. ApoE transports cholesterol to neurons via ApoE 
receptors [3], thereby being involved in the mobilization of lipids in repair, growth and 
maintenance of myelin and axonal membranes [3,4]. The epsilon4 (ε4) allele of the APOE gene 
is a major genetic risk factor for AD [3,4], and meta-analyses demonstrate decreased blood and 
cerebrospinal fluid (CSF) ApoE concentrations in AD [5,6].  
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ApoA-I is mainly produced in the liver and the intestine [7,8]. Although experimental data 
suggest that ApoA-I can be secreted from cerebral microvascular endothelial porcine cells [9], 
there is no evidence of ApoA-I synthesis in the human CNS [8,10]. ApoA-I gains access to the 
CNS by crossing the blood-cerebrospinal fluid barrier via specific cellular mediated transport, 
and to a lesser extent by transport across the blood-brain barrier [11]. ApoA-I has been less well 
studied than ApoE, but experimental data suggest that Apo A-I might protect from amyloid 
toxic effects [12]. Overexpression of human ApoA-I in a mouse AD model (APP/PS1/AI mice) 
prevented learning and memory deficits [13], whereas lack of ApoA-I in mice aggravated 
memory deficits and increased cerebral amyloid angiopathy [14]. ApoA-I administration 
protected hippocampal neuronal cultures from β-amyloid (Aβ)-induced oxidative stress and 
neurodegeneration [15]. In the human brain, ApoA-I has been found in association with Aβ 
deposits [16], and complexes between ApoA-I and Aβ can be detected in CSF from AD patients 
[15].  
In serum or plasma, several studies have shown decreased ApoA-I concentration in AD patients 
[17,18], although unchanged ApoA-I levels have also been observed [19]. In a longitudinal 
study, high serum ApoA-I was associated with reduced risk of dementia [20]. In terms of CSF, 
two in vivo studies showed normal ApoA-I concentration in AD [21,22], whereas in another 
small in vivo study, decreased CSF ApoA-I concentration was observed in seven AD patients 
compared to seven controls [23]. Furthermore, CSF ApoA-I concentration was reduced in two 
postmortem studies [24,25]. 
The apolipoproteins ApoA-I and ApoE may be involved in the pathogenesis of brain disorders 
leading to cognitive decline, but the nature of this involvement is still not fully clear. In a well 
characterized mono-center cohort of patients with cognitive impairment and matched healthy 
controls, we determined plasma lipids as well as plasma and CSF concentrations of ApoA-I and 
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ApoE. We also studied whether there were associations with MMSE score and CSF levels of 
AD biomarkers. 
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Materials and methods 
Study participants 
The study participants as well as AD CSF biomarkers have been reported previously [26]. The 
study consisted of consecutively recruited Caucasian patients admitted by their general 
practitioner for evaluation of cognitive impairment to a memory clinic in Falköping, Sweden. 
The participants were recruited by a single specialized physician (P.J.) 2000-2008. Inclusion 
criteria, besides being referred to Falköping Hospital for evaluation of suspected dementia, were 
age 65-80 years, body mass index (BMI) 20-26 kg/m², and waist: hip ratio 0.65-0.90 in women 
and 0.70-0.95 in men. Exclusion criteria were serum creatinine > 175 mmol/L, diabetes 
mellitus, previous myocardial infarction, malignancy including brain tumor, subdural 
hematoma and ongoing alcohol abuse. 
Control subjects were recruited contemporaneously from the same geographical area among 
spouses of the included patients and by advertisements in local newspapers. The controls had 
no subjective symptoms of cognitive dysfunction but otherwise, inclusion and exclusion criteria 
were similar as those in the patients. Totally, 60 patients and 20 healthy controls were recruited. 
However, in this analysis, patients treated with lipid lowering agents were excluded. Therefore, 
56 patients (29 men and 27 women) and 18 healthy controls (10 men and 8 women) were 
included in the present study.  
The presence or absence of dementia was diagnosed according to the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV), criteria. Patients with dementia were 
classified as suffering of Alzheimer’s disease (AD) [27], vascular dementia (VaD) according 
to the requirements by NINDS-AIREN [28] or the guidelines by Erkinjuntti et al. for the 
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subcortical type of VaD [29]. Dementia with Lewy bodies (DLB) and frontotemporal lobe 
dementia (FTD) were diagnosed as described previously [26].   
Mild cognitive impairment (MCI) was diagnosed in patients with cognitive impairment that did 
not fulfil the criteria for dementia [30]. Patients with MCI were followed at least annually for a 
median of 3 (range 1-7) years to evaluate whether they later developed dementia. All diagnoses 
were assessed by an independent specialized physician [26]. During the follow-up visits, 13 
MCI patients remained in stable cognitive function (SMCI). Others progressed, during the 
follow-up period, to dementia and were diagnosed with AD (n = 5), VaD (n = 3), or FTD (n = 
1). MCI patients diagnosed with AD on follow-up visits did not differ in CSF levels of the AD 
biomarkers β-amyloid1-42 (Aβ1-42), total-tau (T-tau) or phosphorylated tau protein (P-tau) from 
patients with established AD at baseline (data not shown). Totally, the study population 
consisted of AD dementia or MCI diagnosed with AD dementia upon follow-up (n = 29), other 
dementias (n = 14), SMCI (n = 13), and healthy controls (n = 18). The distribution of diagnoses 
in the other dementia group was VaD or MCI diagnosed with VaD upon follow-up (n = 9), 
DLB (n = 4), and MCI diagnosed with FTD upon follow-up (n = 1). 
Ethical considerations  
The study was approved by the ethical committee of University of Gothenburg, and informed 
consent was obtained from all participants. 
Cognitive and physical examination 
Before the test day, a mini-mental state examination (MMSE) [31] was performed. On the test 
day morning with the patients in the fasted state, before lumbar puncture was performed, body 
weight was measured to the nearest 0.1 kg, body height was measured barefoot to the nearest 
0.01 m, and body mass index (BMI) was calculated as the weight in kilograms divided by the 
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height in meters squared. Waist circumference and hip girth was measured as described 
previously [26].  
CSF sampling 
All CSF samples were collected by lumbar puncture in the L3/L4 or L4/L5 interspace at the 
standardized time point 8.30-9.00 am. The first 12 mL of CSF was collected in a polypropylene 
tube and immediately transported to the local laboratory for centrifugation at 2.000g at +4˚C 
for 10 minutes. The supernatant was pipetted off, gently mixed to avoid possible gradient 
effects, and aliquoted in polypropylene tubes that were stored at -80oC pending biochemical 
analyses, without being thawed and re-frozen.  
Blood samples 
Blood samples were drawn in the morning in the fasted state. Plasma concentrations of total 
cholesterol, HDL-cholesterol, and triglycerides were analyzed in the routine clinical setting. 
Plasma samples for determination of ApoA-I and ApoE concentrations were stored at -80oC 
pending biochemical analyses, without being thawed and re-frozen.  
Biochemical procedures 
Plasma concentrations of total cholesterol, HDL-cholesterol, and triglycerides were measured 
using clinical routine methods on Roche Hitachi (717 and 911) and Siemens Advia (1650 and 
1800) instruments. Cross-calibration measurements showed similar values for the methods used 
and reference ranges were identical. CVs were < 7 %.  LDL-cholesterol was calculated 
according to Friedewald’s formula [32]. 
All biochemical analyses of ApoA-I and ApoE concentrations as well as CSF AD biomarkers 
were performed at the Clinical Neurochemistry Laboratory in Mölndal, Sweden, with the 
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analyst blinded to the clinical diagnoses and other clinical information. All analyses were done 
at one occasion, using the same batch of reagents. Saknas här: metodbeskrivning för ApoA-I 
och ApoE i plasma och CSF. (Verkar ha blivit analyserade med metod från Linco.) 
 CSF Aβ1-42 levels were determined using the INNOTEST® ELISA assay technology 
(Innogenetics, Ghent, Belgium) [33]. The axonal damage marker CSF T-tau and CSF 
concentrations of tau phosphorylated at threonine 181 (P-tau181) were measured using 
INNOTEST® ELISA assays [34,35]. 
Apolipoprotein E (APOE) (gene map locus 19q13.2) genotyping was performed by 
minisequencing as described previously in detail [36]. Genotypes were obtained for the two 
SNPs, which are used to unambiguously define ε2, ε3, and ε4 alleles (rs7412 and rs429358). 
Statistical analyses 
The descriptive statistical results are given as the median (25th-75th percentile) if not otherwise 
stated. Between-group differences were assessed using the non-parametric Kruskal-Wallis test 
for multiple variables, followed by the Mann-Whitney U test for pair-wise comparisons. 
Correlations were sought using the Spearman rank order correlation test.  Significance was 
obtained if the two-tailed P-value was ≤ 0.05.  
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Results 
The patients and healthy controls were comparable in terms of age, gender, BMI, and waist: hip 
ratio (Table 1). AD biomarkers have been reported previously [26]. None of the investigated 
variables in plasma or CSF correlated with age or CSF/serum albumin ratio (data not shown).  
Plasma concentrations of lipids and apoplioproteins 
Plasma triglyceride concentration was increased in AD and SMCI patients compared to controls 
(P < 0.05 and P < 0.01, respectively) (Table 2). In addition, plasma triglyceride concentration 
was elevated in SMCI patients compared to patients with other dementias (P < 0.05). Plasma 
concentrations of total cholesterol, HDL-cholesterol, and LDL-cholesterol as well as plasma 
concentrations of ApoA-I and ApoE were similar in all groups (Table 2). 
CSF concentrations of ApoA-I and ApoE 
CSF ApoA-I concentration was decreased in AD patients compared to SMCI patients and 
healthy controls (both P < 0.05) (Fig. 1A). CSF ApoE was reduced in other dementias compared 
to AD and healthy controls (P < 0.05 and P < 0.01, respectively) (Fig. 1B). The ratio between 
CSF and plasma concentrations of ApoA-I (CSF: plasma ApoA-I ratio) was decreased in AD 
and other dementias compared to healthy controls (P < 0.01 and P < 0.05, respectively) (Fig. 
1C). Furthermore, also the CSF: plasma ApoE ratio was decreased in AD and other dementias 
compared to the controls (P < 0.05 and P < 0.01, respectively) (Fig. 1D).  
Lipids and apolipoproteins in relation to APOE ε4 allele distribution (Table 3)  
In the total study population, plasma total cholesterol concentration was increased in study 
participants that were heterozygous or homozygous in terms of the APOE ε4 allele compared 
to participants lacking the APOE ε4 allele (both P < 0.05) (Table 3). Plasma HDL-cholesterol 
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concentration was increased in participants with heterozygous APOE ε4 allele distribution 
compared to no APOE ε4 allele (P < 0.05). Plasma and CSF concentrations of other lipids and 
apolipoproteins as well as CSF: plasma ratios of apolipoproteins were statistically similar in all 
groups (Table 3).  
Correlation analysis 
We evaluated whether concentrations of apolipoproteins correlated with MMSE score and CSF 
AD biomarkers. In the total study population (n = 74), CSF ApoA-I concentration correlated 
positively with MMSE score (r = 0.26, P < 0.05), and negatively with CSF P-tau concentration 
(r = -0.25, P < 0.05).  CSF ApoE concentration correlated positively with CSF concentrations 
of Aβ1-42 (r = 0.25, P < 0.05), T-tau (r = 0.27, P < 0.05) and P-tau (r = 0.39, P < 0.001). CSF: 
plasma ApoA-I ratio correlated positively with MMSE (r = 0.31, P = 0.01), but not with CSF 
AD biomarkers. CSF: plasma ApoE ratio did not correlate with MMSE or CSF AD biomarkers.    
In AD patients (n = 29), CSF ApoE concentration correlated positively with CSF concentrations 
of T-tau (r = 0.44, P < 0.05) as well as P-Tau (r = 0.52, P < 0.01). CSF ApoA-I concentration 
or CSF: plasma ratios of ApoA-I and ApoE did not correlate with MMSE score or CSF AD 
biomarker concentrations in AD patients.   
 
 
 
 
Discussion 
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In the present mono-center study, we included community-dwelling patients under primary 
evaluation for cognitive impairment and thus in the early phases of cognitive decline (median 
MMSE score in the AD group was 23). Strictly defined procedures were followed in terms of 
diagnostic procedures and clinical assessments including lumbar puncture [26], and ApoA-I 
and ApoE were analyzed using standardized methods in plasma and CSF samples that had 
previously not been thawed. Patients and controls were matched in terms of age, gender, BMI, 
and waist: hip ratio and none of the study participants had diabetes mellitus or received medical 
treatment with lipid lowering agents, glucocorticoids, or acetylcholine esterase inhibitors [26]. 
Thus, several factors that could influence lipids and apolipoproteins were highly standardized. 
However, a limitation is the cross-sectional design, and changes over time could therefore not 
be studied.  
We found increased plasma triglyceride concentration in AD and SMCI patients compared to 
healthy controls whereas other lipids in plasma were similar between groups. In previous 
studies of AD, circulating HDL-cholesterol was reduced in some studies [37,38], total 
cholesterol and/or LDL-cholesterol were increased in part of the studies [38-40], and plasma 
triglyceride concentrations were increased [37] or normal [39,40]. Therefore, most studies 
including the present one show impaired circulating lipid pattern in AD although concentrations 
of cholesterol fractions and triglycerides have been relatively variable between studies. 
Plasma ApoA-I concentration was similar in all study groups. Although most previous studies 
have shown decreased circulating ApoA-I in AD [17,18], unchanged plasma ApoA-I 
concentration has also been observed [19]. Furthermore, ApoA-I polymorphisms could 
influence the risk of AD [41]. The A allele of the APOA1 -75bp G/A polymorphism was 
associated with increased risk of early-onset nonfamiliar AD [41]. The natural variant of ApoA-
I found in carriers of the ApoA-I Milano polymorphism provides protection from 
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atherosclerosis [42]. A recombinant ApoA-I Milano/phospholipid complex (ETC-216) reduced 
coronary atherosclerosis in patients with acute coronary syndromes [43], which has generated 
interest in using ApoA-I mimetics as therapeutic agents [44]. In a mouse AD model (APPSwe-
PS1 Delta E9 mice), addition of an oral ApoA-I mimetic peptide to lipid-lowering statin 
treatment inhibited Aβ deposition and improved cognitive function [45].  
In our study, CSF ApoA-I concentration was decreased in AD compared to SMCI and healthy 
controls. Two previous in vivo studies showed normal [21] or a non-significant trend to 
increased [22] CSF ApoA-I concentration in AD, whereas another study revealed decreased 
CSF ApoA-I in seven AD patients compared to seven controls [23]. In addition, two 
postmortem studies displayed reduced CSF ApoA-I in AD [24,25]. Furthermore, we observed 
reduced CSF: plasma ApoA-I ratio in AD patients compared to the controls. This ratio has 
previously not been studied in AD as earlier studies did not measure both circulating and CSF 
ApoA-I [21-25]. Experimental data suggest that ApoA-I can be transported into the CNS [11], 
while ApoA-I production has not been documented in the human CNS [8,10]. Therefore, the 
reduced CSF: plasma ApoA-I ratio in our AD patients could suggest reduced passage of ApoA-
I through blood-cerebrospinal and/or the blood-brain barrier. However, it cannot be excluded 
that ApoA-I passes normally into the CNS and that Apo-I then is lowered due to 
aggregation/sequestration of ApoA-I around amyloid plaques in the AD brain.  
In the present study, plasma as well as CSF ApoE concentration was similar in AD patients as 
that in the controls. After the first study showing a reduction in CSF ApoE levels in AD [REF], 
most studies have confirmed such a decrease [21,46-48], although some found either normal 
[49], or increased [21,50] CSF ApoE concentration in AD. A meta-analysis also revealed 
decreased ApoE both in blood and CSF from AD patients [5,6]. A recent study in which ApoE 
was quantified in plasma and CSF using mass spectrometry-based assays specific for the E3 
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and E4 isoforms, respectively, revealed an age-related increase in both isoforms (ref: Baker-
Nigh AT, Mawuenyega KG, Bollinger JG, Ovod V, Kasten T, Franklin EE, Liao F, Jiang H, 
Holtzman D, Cairns NJ, Morris JC, Bateman RJ. J Biol Chem. 2016 Oct 28. pii: 
jbc.M116.721779. [Epub ahead of print]). Presence of amyloid pathology, determined by 
amyloid PET, was associated with increased CSF ApoE3 concentration, but unaltered ApoE4 
concentration. Moreover, there was no correlation for total ApoE, ApoE3 and ApoE4 
concentrations between plasma and CSF, suggesting that CNS and peripheral ApoE are separate 
pools and differentially regulated. In contrast to the unchanged CSF:plasma ApoE ratio in AD 
in a previous study [51], we observed decreased CSF:plasma ApoE ratio in AD patients 
compared to the controls. An animal study [52], as well as a human study performed before and 
after liver transplantation [53], indicated that ApoE in CNS/CSF is predominantly synthesized 
locally. This suggests that the decreased CSF: plasma ApoE ratio in our study could be caused 
by increased reutilization of ApoE-lipid complexes as part of a generalized brain repair process 
in AD, or that ApoE might be aggregated /sequestered in senile plaques and neurofibrillary 
tangles.  
We observed higher plasma total cholesterol in study participants carrying the APOE ε4 allele 
compared to non-carriers. Furthermore, plasma HDL-cholesterol concentration was increased, 
and LDL-cholesterol tended to be increased, in APOE ε4 allele carriers. However, plasma and 
CSF concentrations of ApoA-I or ApoE were not significantly affected by APOE ε4 allele 
distribution. Possession of the ε4 allele has, in the circulation, been related to a disturbed pattern 
of lipids, ApoA-I, and ApoE in some [17,54,55] but not all [56,57] previous studies. CSF ApoE 
concentration was not associated with ApoE ε4 genotype in several studies [46,47], whereas 
the relation between the ApoE ε4 genotype and CSF ApoA-I concentration has previously not 
been determined. In summary, although there has been mixed results, some studies including 
our study have found that the ApoE ε4 genotype influences the circulating pattern of 
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lipids/apolipoproteins but not CSF concentrations of apolipoproteins.  
In the total population, CSF ApoA-I concentration as well as CSF: plasma ApoA-I ratio 
correlated positively with MMSE score. In addition, CSF ApoA-I correlated negatively with 
CSF P-Tau in the total study population but not in AD patients. Furthermore, CSF ApoE 
concentration correlated positively with CSF concentrations of T-tau and P-Tau both in the total 
population and in AD patients. Therefore, the results of the correlation analyses might suggest 
that CSF levels of apolipoproteins to some extent associate with cognitive decline and/or AD 
disease status.  
We measured lipids and apolipoproteins also in SMCI and other dementias, conditions with 
different underlying pathogenesis and clinical presentation than AD. One in vivo study [22] and 
one postmortem study [25] showed unchanged CSF ApoA-I concentration in non-AD 
dementia. In our study, serum and CSF concentrations of ApoA-I were unchanged in SMCI and 
other dementias, whereas the CSF: plasma ApoA-I ratio was reduced in other dementias. In the 
line with the results of another study [47], we observed reduced CSF ApoE concentration in 
other dementias compared to the controls. Furthermore, plasma triglyceride concentration was 
increased in SMCI patients compared to the controls. However, there were relatively few 
patients in the other dementia and SMCI groups and the number of each specific diagnosis was 
comparatively low in the other dementia group. Therefore, the role of ApoA-I in dementing 
disorders other than AD needs to be explored in further studies.     
In conclusion, in a homogenous, well-controlled study cohort, CSF ApoA-I concentration was 
decreased in AD patients and was associated with measures of cognitive function and AD 
disease status. The mechanisms underlying the decreased CSF: plasma ratios of ApoA-I and 
ApoE in AD could include increased sequestration of the apolipoproteins in the CNS or in case 
of the CSF: plasma ApoA-I ratio, decreased passage from the periphery into the CNS could 
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speculatively be of importance. Disturbances of lipids/apolipoproteins were seen also in 
patients with SMCI and other dementias, but these groups were small and the number of each 
specific diagnosis was relatively low in the other dementia group. 
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Legend to Figures 
Figure 1 
A) CSF ApoA-I concentration, B) CSF ApoE concentration, C) CSF:serum ApoA-I ratio, and 
D) CSF:serum ApoE ratio in the study population of patients with AD (n=29), other dementias 
(n=14), SMCI (n=13), and healthy controls (n=18). Values in the box plots are given as medians 
(horizontal lines), 25th-75th percentiles (boxes), and ranges (whiskers). Between-group 
differences were assessed using the Kruskal-Wallis test for multiple variables, followed by the 
Mann-Whitney U test for pair-wise comparisons.  
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Values are given as the median (25th-75th percentile). The P-values in the right column refers 
to differences between all four groups using the Kruskal-Wallis test for multiple variables. 
Comparisons between two separate groups were performed using the Mann-Whitney U test. 
 aP < 0.0001 vs. controls; bP < 0.0001 vs. SMCI; cP < 0.001 vs. controls; dP < 0.001 vs. SMCI;  
eP < 0.01 vs. controls; fP < 0.05 vs. controls; gP < 0.0001 vs. other dementias  
 
 
 
 
 
 
Table 1. Age, anthropometric measures, MMSE score, and CSF biomarkers in the total study population of 56 
patients with cognitive impairment and 18 healthy matched controls.  
 AD 
(n = 29) 
Other dementias 
(n = 14) 
SMCI 
(n = 13) 
Controls 
(n = 18) 
P-values 
Men/women 14/15 10/4 5/8 10/8 0.35 
Age (years) 75 (71-77) 74 (72-76) 72 (69-74) 74 (70-78) 0.32 
BMI (kg/m2) 22.6 (21.7-25.0) 24.2 (20.9-25.6) 24.0 (23.1-26.0) 24.3 (23.3-25.2) 0.29 
Waist/hip ratio 0.87 (0.77-0.90) 0.90 (0.87-0.93) 0.82 (0.78-0.88) 0.88 (0.83-0.91) 0.06 
MMSE score  23 (19-25)a,b 24 (20-26)c,d 29 (27-29) 28 (27-29) < 0.0001 
Aβ1-42 (ng/L) 430 (326-490)a,d 400 (338-801)e 671(528-851)f 990 (785-1031) < 0.0001 
T-tau (ng/L) 595 (413-729)a,b,g 312 (247-381) 270 (224-393) 324 (223-405) < 0.0001 
P-tau (ng/L) 97 (78-113)c,d,g 47 (32-63) 60 (38-76) 63 (47-79) < 0.0001 
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Table 2. Plasma concentrations of lipids and apolipoproteins in the study population of 56 patients with cognitive 
impairment and 18 healthy matched controls.   
 
AD 
(n = 29) 
Other dementias 
(n = 14) 
SMCI 
(n = 13) 
Controls 
(n = 18) 
P-
values 
Trigycerides 
(mmol/L) 
1.40 (1.00-1.67)a 1.04 (0.81-1.30) 1.42 (1.07-2.33)b,c 0.98 (0.72-1.34) 0.01 
Total cholesterol 
(mmol/L) 
6.30 (5.50- 6.90) 5.50 (4.65-6.20) 6.40 (5.10-7.55) 5.95 (5.40-6.30) 0.19 
HDL-cholesterol 
(mmol/L) 
1.60 (1.44-1.80) 1.64 (1.48-1.99) 1.51 (1.21-1.59) 1.51 (1.23-1.70) 0.22 
LDL-cholesterol 
(mmol/L) 
3.82 (3.41-4.32) 3.29 (2.65-3.69) 3.60 (3.25-5.15) 3.84 (3.32-4.18) 0.13 
ApoA-I (µg/mL) 3826 (2973-5013) 3710 (3377-4878) 3714 (3139-4796) 2686 (1993-3789) 0.055 
ApoE (µg/mL) 160 (50 – 341) 148 (50-236) 175 (82-506) 80 (32-115) 0.13 
Values are given as the median (25th-75th percentile). The P-values in the right column refers 
to differences between all four groups using the Kruskal-Wallis test for multiple variables. 
Comparisons between two separate groups were performed using the Mann-Whitney U test. 
 aP < 0.05 vs. controls; bP < 0.01 vs. controls; cP < 0.05 vs. other dementias 
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Table 3. Levels of lipids and apolipoproteins in relation to APOE ε4 allele distribution in the total study 
population (n = 74). 
APOE ε4 allele  None 
(n = 37, 55%) 
Heterozygous 
(n = 20, 30%) 
Homozygous 
(n = 10, 15%) 
P-
values 
Plasma values     
Triglycerides (mmol/L) 1.00 (0.78-1.50) 1.18 (1.06-1.65) 1.40 (0.82-1.75) 0.12 
Total cholesterol (mmol/L) 5.60 (5.20-6.30) 6.20 (5.85-6.83)a 6.75 (6.10-7.40)a 0.03 
HDL-cholesterol (mmol/L) 1.46 (1.24-1.70) 1.64 (1.56-1.90)a 1.73 (1.44-2.13) 0.04 
LDL-cholesterol (mmol/L) 3.47 (3.10-3.99) 3.89 (3.54-4.66) 3.97 (3.53-4.82) 0.21 
ApoA-I (µg/mL) 3487 (2419-4459) 3589 (2800-4448) 3792 (3213-4864) 0.53 
ApoE (µg/mL) 109 (68-238) 79 (43-294) 97 (33-335) 0.89 
CSF values     
ApoA-I (µg/mL) 2.74 (2.12-3.94) 3.40 (2.63-3.90) 3.12 (2.85-3.48) 0.62 
ApoE (µg/mL) 4.87 (4.07-7.52) 4.83 (3.65-6.09) 4.42 (3.15-6.39) 0.42 
CSF/plasma ratios     
ApoA-I (%) 0.088 (0.057-0.175) 0.094 (0.069-0.116) 0.077 (0.051-0.112) 0.62 
ApoE (%) 4.6 (2.3-12.0) 5.8 (1.7-14.3) 4.8 (1.9-14.7) 0.90 
 
APOE genotyping was not performed in 7 of the study participants. Values are given as the 
median (25th-75th percentile). The P-values in the right column refers to differences between 
all three groups using the Kruskal-Wallis test for multiple variables. Comparisons between two 
separate groups were performed using the Mann-Whitney U test.  
aP < 0.05 vs. no APOE ε4 allele 
 
